Fairvalue-Calculator Fairvalue-Calculator
EN DE

PT Sariguna Primatirta Tbk, (CLEO) Fair Value & Analysis

Consumer Defensive · ID · Market cap 9.3T IDR

Price380.00 IDR
Fair Value334.09 IDR
Upside-12.1%
Quality92/100
Evidence: High Range 174.76 IDR – 526.15 IDR

Analysis

PT Sariguna Primatirta Tbk, (CLEO) currently trades at 380.00 IDR, while our model-based Fair Value estimate is 334.09 IDR — implying the stock looks roughly 12.1% overvalued today. We read business quality at 92/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

PT Sariguna Primatirta Tbk, together with its subsidiaries, produces and sells bottled drinking water products in Indonesia. The company operates through the Bottle, Non-Bottle, and Others segments. The company also has wholesale trading of food and beverages and the production and distribution of ice for food, beverage, and other uses. It sells drinking water under the Cleo, Super O2, VIO, Cleo Plantine, Anda, and S-Tube brands; and green tea under the NOGU brand. The company was formerly known as PT Sari Guna and changed its name to PT Sariguna Primatirta Tbk in December 1988. The company was founded in 1988 and is headquartered in Sidoarjo, Indonesia. PT Sariguna Primatirta Tbk operates as a asubsidiary of PT Tancorp Global Abadi.

Open the full interactive analysis →

Similar stocks

The Coca-Cola Company (CCC3) -43% PepsiCo, Inc (PEP) -34% Monster Beverage Corporation (MNST) -40% Nongfu Spring Co (9633) +92% Coca-Cola FEMSA, S.A. (C2CA34) -57% Keurig Dr Pepper Inc (KDP) +4%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.